Loading…
Polyclonal Anti-PrP Auto-antibodies Induced with Dimeric PrP Interfere Efficiently with PrPSc Propagation in Prion-infected Cells
Prion diseases are neurodegenerative infectious disorders for which no prophylactic regimens are known. In order to induce antibodies/auto-antibodies directed against surface-located PrP c , we used a covalently linked dimer of mouse prion protein expressed recombinantly in Escherichia coli . Employ...
Saved in:
Published in: | The Journal of biological chemistry 2003-05, Vol.278 (20), p.18524-18531 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Prion diseases are neurodegenerative infectious disorders for which no prophylactic regimens are known. In order to induce
antibodies/auto-antibodies directed against surface-located PrP c , we used a covalently linked dimer of mouse prion protein expressed recombinantly in Escherichia coli . Employing dimeric PrP as an immunogen we were able to effectively overcome autotolerance against murine PrP in PrP wild-type
mice without inducing obvious side effects. Treatment of prion-infected mouse cells with polyclonal anti-PrP antibodies generated
in rabbit or auto-antibodies produced in mice significantly inhibited endogenous PrP Sc synthesis. We show that polyclonal antibodies are binding to surface-located PrP c , thereby interfering with prion biogenesis. This effect is much more pronounced in the presence of full IgG molecules, which,
unlike Fab fragments, seem to induce a significant cross-linking of surface PrP. In addition, we found immune responses against
different epitopes when comparing antibodies induced in rabbits and PrP wild-type mice. Only in the auto-antibody situation
in mice an immune reaction against a region of PrP is found that was reported to be involved in the PrP Sc conversion process. Our data point to the possibility of developing means for an active immunoprophylaxis against prion diseases. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.M210723200 |